Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Capital Expenditures: 2020-2024

Historic Capital Expenditures for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $337,262.

  • SAB Biotherapeutics' Capital Expenditures fell 18.40% to $55,377 in Q4 2024 from the same period last year, while for Dec 2024 it was $337,262, marking a year-over-year increase of 71.07%. This contributed to the annual value of $337,262 for FY2024, which is 71.07% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Capital Expenditures stood at $337,262 for FY2024, which was up 71.07% from $197,154 recorded in FY2023.
  • SAB Biotherapeutics' 5-year Capital Expenditures high stood at $12.7 million for FY2020, and its period low was $197,154 during FY2023.
  • Its 3-year average for Capital Expenditures is $900,277, with a median of $337,262 in 2024.
  • In the last 5 years, SAB Biotherapeutics' Capital Expenditures tumbled by 90.90% in 2023 and then spiked by 71.07% in 2024.
  • SAB Biotherapeutics' Capital Expenditures (Yearly) stood at $12.7 million in 2020, then decreased by 14.04% to $10.9 million in 2021, then slumped by 80.20% to $2.2 million in 2022, then plummeted by 90.90% to $197,154 in 2023, then soared by 71.07% to $337,262 in 2024.